Sebastian Heersink, MD
Ophthalmology · Dothan, ALNPI 1376701391
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (46.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Glaukos Corporation accounts for 63.7% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2024 at $17,776 and has fallen 76.0% since, to $4,265 in 2025. Among ophthalmology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 482 payments — averaging $68.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$21K
- Carl Zeiss Meditec Cataract Technology Inc.$4K
- Iridex Corporation$2K
- Ivantis, Inc$820
- Alcon$605
- Omeros Corporation$559
- plus $4K from 24 others
Across 1,174 payments — averaging $3313.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$2M
- AbbVie$911K
- Ocular Therapeutix, Inc.$515K
- Alcon Research LLC$337K
- Sight Sciences, Inc.$119K
- Johnson & Johnson Surgical Vision, Inc.$15K
- plus $17K from 3 others
What the payments were for
- Consulting fees$4,90015%
- Speaking & faculty fees$2,0266%
- Food & beverage$10,73132%
- Gifts$840%
- Other$15,49647%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 263 | $21,164 |
| Carl Zeiss Meditec Cataract Technology Inc. | 2 | $4,011 |
| Iridex Corporation | 3 | $2,029 |
| Ivantis, Inc | 9 | $820 |
| Alcon | 35 | $605 |
| Omeros Corporation | 34 | $559 |
| Rayner Intraocular Lenses Limited | 26 | $498 |
| Nordic Pharma, Inc. | 1 | $480 |
| AbbVie(2 entities) | 11 | $406 |
| Carl Zeiss Meditec, Inc. | 1 | $400 |
| Sight Sciences, Inc. | 5 | $252 |
| NEW World Medical,inc. | 18 | $224 |
| Novartis | 11 | $197 |
| Tarsus Pharmaceuticals, Inc. | 10 | $195 |
| Bausch & Lomb Americas Inc. | 8 | $183 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $158 |
| Dompe US, Inc. | 2 | $146 |
| Amgen | 1 | $120 |
| Harrow Eye, LLC | 5 | $116 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $92 |
| Ocular Therapeutix, Inc. | 5 | $90 |
| Quidel Corporation | 1 | $82 |
| Oyster Point Pharma, Inc. | 4 | $77 |
| Eyepoint US, Inc. | 5 | $67 |
| Kala Pharmaceuticals, Inc. | 4 | $64 |
| Nova Eye, Inc. | 2 | $62 |
| Sun Pharmaceutical Industries Inc. | 2 | $48 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Rxsight Inc | 1 | $26 |
| Shire North American Group Inc | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus$646
- Lacrifill$480
- CT Lucia$400
- Cataract Suite$400
- LUMERA$400
- XEN GLAUCOMA TREATMENT SYSTEM$144
- UPLIZNA$120
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$116
- iAccess Precision Blade$116
- Oxervate$114
- PROLENSA$100
How this compares
$33,236 in reported general payments places this provider in the 95th percentile of 197 ophthalmology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 107 | $202,218 |
| RestasisCyclosporine | 115 | $99,027 |
| TyrvayaVarenicline Tartrate | 47 | $51,185 |
| Prednisolone Acetate | 873 | $46,937 |
| Ketorolac Tromethamine | 1,894 | $42,633 |
| XiidraLifitegrast | 49 | $38,807 |
| MieboPerfluorohexyloctane/Pf | 42 | $31,657 |
| ProlensaBromfenac Sodium | 74 | $26,061 |
| Lotemax SmLoteprednol Etabonate | 76 | $19,378 |
| VyzultaLatanoprostene Bunod | 38 | $17,013 |
| Cyclosporine | 29 | $13,978 |
| BesivanceBesifloxacin Hcl | 35 | $8,919 |
| LumiganBimatoprost | 24 | $8,111 |
| Bromfenac Sodium | 39 | $7,545 |
| Ciprofloxacin Hcl | 408 | $5,237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $195 | $202,218107 claims |
| AbbVieRestasis, Lumigan | $406 | $107,138139 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $183 | $87,476129 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Besivance, Loteprednol Etabonate | $158 | $57,004204 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $77 | $51,18547 claims |
| AlconSimbrinza | $605 | $3,07115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 197 ophthalmology providers in Alabama.
Other ophthalmology in Dothan
- Harsha SenDothan$11K
- Kirk SturridgeDothan$11K
- Aaron McKinleyDothan$8K
- Warren ThompsonDothan$6K
- Marius HeersinkDothan$3K
- Jorge ArangoDothan$3K
- Bret FisherHomewood$545K
- Caroline WatsonHuntsville$292K
- Ronald GrossFairhope$143K
- Kristin BainsBirmingham$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.